ascopubs.org

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First ...

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
ascopubs.org

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering ...
ascopubs.org

Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin

Supported by a generous gift from the Elisabeth and Ad Creemers estate and gifts to the fund to support Peritoneal Metastasis Research at UC San Diego. The following represents disclosure information ...
ascopubs.org

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor ...

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...
ascopubs.org

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text component ...
ascopubs.org

Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014.

Contribution of Lynch syndrome to early onset malignancy in Ireland.
ascopubs.org

Journal of Clinical Oncology

Outcome, costs and dollar value of docetaxel and abiraterone in prostate cancer. A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in ...
ascopubs.org

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen. Further study is needed to fully evaluate oxaliplatin reintroduction.
ascopubs.org

Precision delivery of RAS-inhibiting siRNA to pancreatic cancer via peptide-based nanoparticles.

Prognostic value of CD8+CD45RO+ tumor-infiltrating lymphocytes (TIL) and PD-L1 in cholangiocarcinoma. This is an ASCO Meeting Abstract from the 2017 Gastrointestinal Cancers Symposium. This abstract ...
ascopubs.org

A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.

Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. This is an ASCO Meeting Abstract from the 2014 ASCO ...
ascopubs.org

Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study

Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients PURPOSE: To determine the response rate of the ...
ascopubs.org

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. This is an ASCO Meeting Abstract from the ...